The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride.Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems.
We found statistically significant relationship between the SRD5A2 gene Ala49Thr (OR=2.3; CI 95%, 1.04-5.1; p=0.01<0.05) , but not the other polymorphisms, and B</span>PH.
<b>Results:</b><i>SRD5A2</i> rs9282858 (A49T) polymorphism showed a significant correlation with increased B</span>PH susceptibility under allele T vs.allele A genetic model (OR = 2.51, 95% CI = 1.29-4.88) in total analysis, and stratification analysis by ethnicity also revealed a similar association in Caucasian group under the same contrast.